News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Puma Biotechnology (PBYI) Announces Late-Breaking Oral Presentation On Neratinib In NSCLC With HER2 Mutations At ESMO 2014


9/3/2014 8:58:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain. The presentation entitled “Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations: An international randomized Phase II study” will occur on September 29, 2014.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES